TLX250-CDx EAP

NCT06090331

Age

Gender

Conditions

Learn about this study

This Expanded Access Program (EAP) provides access to 89Zr-DFO-girentuximab (TLX250-CDx) for kidney cancer imaging in the United States. The program allows access to investigational products outside of a clinical trial to patients for whom there are no comparable or satisfactory alternate options.

Who can participate?

Participating in clinical research is a significant, personal decision. Before enrolling, the study team will fully explain the research and provide an Informed Consent Form that outlines possible benefits and risks. This is your chance to ask questions and consult with your doctor to determine if the study is right for you.

You may be able to participate if:

  • You have imaging evidence of renal mass(es) obtained from conventional diagnostic imaging with CT or MRI
  • Your healthcare provider determines that TLX250-CDx may be beneficial for your care
  • You meet the eligibility criteria for the expanded access program

 

Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

Find a Site

Select your country and enter your location or use the map to find the closest clinical trial site(s) to you. Once you have found a site, use the site contact details to speak with their team to learn more about the trial eligibility. 

Compassionate use

Telix is often contacted to provide access to our products under compassionate use. We respect the treatment journey of the patient and the independence of healthcare professionals in making their treatment decisions. Telix tries to accommodate such requests whenever it is clinically, ethically and practically feasible to do so.

You can find Telix’s compassionate use policy here:

Policy on Offering Compassionate Use to Investigational Medicines

Request form

    Private Information

    In order to handle an enquiry, we are required to record and maintain the data and personal information about patients that have been provided to us. This may include name and contact details, and eventually patient information, such as initials and medical need summary. The personal information will be processed for the purposes of dealing with enquiries, complying with applicable laws and related internal records keeping purposes. For more information, please consult our Privacy Notice.

    The information provided on this website is for general informational purposes only and may not reflect all current or upcoming clinical trials being conducted with Telix’s investigational assets. While we strive to keep the content up to date, inclusion of a trial on this site does not guarantee its availability, eligibility criteria, or status. For the most accurate and comprehensive information, please consult ClinicalTrials.gov.

    If you are an individual interested in potentially enrolling in a clinical trial, please contact your health care provider for more information about what trials may be right for you.